Top Minds Join GB Sciences’ Think-Tank for the Advancement of Cannabis-based Medicines
LAS VEGAS, March 15, 2018/PR Newswire/–GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce their sponsorship of the 1st Annual “Innovation in Medical Cannabis Therapies” Symposium in Las Vegas, Nevada, on Friday, June 1st, 2018. Top innovators in cannabis tech, biotech, nanotech, and metabolomics are invited to this collaborative discussion, which was designed to explore the necessary advances across multiple fields that are required for the development of safe and effective plant-based medicines.
The GBS philosophy is that real innovation is only possible when researchers are supported to do the work that they love and are given the freedom to do it without the regimented business activities that characterize traditional pharma.
“We predict an explosion of cannabis-based medicines in the next decade; however, there are still key areas where tech and biotech innovations are necessary before plant-based medicines will become a reality,” explains Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. “GB Sciences has developed an innovative research and development program by welcoming and collaborating with researchers who cannot otherwise find a suitable forum or research partner for their work due to their novel approaches in solving problems… in other words, people who think and operate just like us.”
The GBS approach to research is always grounded in solid science and The Life Sciences team, a division of GB Sciences, has discovered that other researches who ascribe to this nontraditional mindset usually find funding and partnering difficult to come by.
“The uncomfortable truth is that traditional pharma has been dabbling in cannabinoid research for fifty years, but they keep falling back on reductionist thinking; like single compounds for single targets and their use of synthetic molecules.” said Dr. Andrea Small Howard.
GBS Life Sciences is currently working with research scientists in seven locations to discover disease-modifying compounds that occur naturally in the cannabis plant and has organized this symposium to gather more like-minded innovators who will create both novel cannabis-based medicines to help the many patients who need therapeutic options, as well as the tech and biotech tools to manufacture and develop those plant-based medicines.
“GB Sciences is committed to promoting innovation in the creation of cannabis therapies, but we know that we cannot do it alone.” Said John Poss, CEO and Chairman of GB Sciences; “Supporting programs like this is our way of encouraging others to join us and to ride this wave of innovation. True cooperation by like-minded people is the only way that this industry can move forward in a positive direction.”
To sign up for the Innovation Conference or for further information visit the Innovation Symposium Registration Page.